Mazor Corporate Presentation NASDAQ, TASE: MZOR

September, 2018





FORWARD LOOKING STATEMENT



This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements, including risks detailed in Mazor Robotics Ltd.'s ("Mazor Robotics" or the "Company") annual reports on Form 20-F filed with the U.S. Securities and Exchange Commission. The following solutions are not yet cleared for use: Mazor X Stealth Edition, Stealth Navigation, Guidewireless

Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.





Mazor Today

- Mazor Core ™ technology with product portfolio and three generations of commercial products
- Supporting and serving 200+ installations and spine programs globally
- 36,000+ Patients, 100s of surgeons, wide spectrum of procedures
- Strategic partnership with Medtronic (Mazor X in spine)
- Successful initiative in ASC market (Ren)
- 55+ peer-reviewed articles and strong evidence of improved patient outcomes
- Ramping up Production










Mazor Robotic Guidance Systems



Predictability, Precision and Efficiency through Innovation





Value creation through robotic workflow







The Mazor Core Technology is the collaboration of four key technologies in Mazor's systems to provide predictable, efficient and precise surgical procedures.

Mazor Core




Surgical Planning Suite



- 3D analytics and virtual tools developed to determine procedure goals and surgical plan. The suite of tools allow creation of a "surgical blueprint" separating the planning from the actual surgery.
- During surgery, the surgeon executes the plan as an efficient and predictable procedure with no anatomical surprises. Implants are pre-selected and prepped, the team knows what to expect.

Anatomy Recognition Engine




- The advanced anatomy recognition engine reads images and recognizes anatomical features based on advanced and proprietry algorithms.
- The engine is fundamental for planning and serves as the underlying technology for features such as vertebral segmentation, image registration and alignment calculations.

Patient Connection Platform



- Set of biocompatible devices that rigidly affix the robotic system/arm to the patient's skeletal anatomy during surgery, ensuring precision through a stable, solid connection.
- This unique feature maintains patientmachine unity during the operation and is a major contributor to accuracy.

Cross-modality image registration



- Sophisticated registration tool with the ability to analyze and match images from different modalities and body positions, e.g. pre-op CT with intra-op fluoroscopy.
- Each vertebra is registered independently of the others and irrespective of modality, date of the image, or patient position.





Robotics and Navigation in One Integrated System Mazor X Stealth Edition*



*Not available for sale in the US, pending FDA clearance

Features

- Robotic Guidance and **Integrated Stealth Navigation**
- Robotic Guided implants
- Sophisticated tools for **Construct Planning**
- Real-Time reconciliation with Plan
- Mazor Core feature set







Benefits

- Assures Performance, closes the surgical loop
- Simplified workflow
- Holistic and personalized patient planning
- Real time verification of surgical goals
- Proven clinical benefits



Renaissance Strategy

U.S. Focus on Ambulatory Surgical Centers



Business Model:

- Cost-sensitive market penetration and development
- ~1000+ sites Addressable Market
- Successful initial efforts with growing number of installations and usage

Global Sales Organization

- Direct activities in the United States
- Active distributors in China, Taiwan, Australia, Thailand, Vietnam, Germany


Technology

- Mazor Core + Brain
- 10% of accounts include Renaissance Brain



Accelerated Clinical Utilization Driving MIS and Serving Patients





Isador Lieberman, MD, MBA, FRCSC, Plano, Texas, USA

"If you do spine surgery for a living, this will come naturally to you...This is the future of spinal surgery."



Evidence-based Medicine From Accuracy to Outcomes



Consistent Accuracy with Improved Outcomes

NEUR OSURGERY

Spinal Robotics: Current Applications and **Future Perspectives**

Florian Roser, MD, PhD Marcos Tatagiba, MD, PhD


pine lournal


Even though robotic technology holds great potential for performing spinal surgery and advancing neurosurgical techniques, it is of utmost importance to establish its practicality and to demonstrate better clinical outcomes compared with traditional techniques, especially in the current cost-effective era. Several systems have proved to be safe and reliable in the execution of tasks on a routine basis, are commercially available, and are used for specific indications in spine surgery. However, workflow, sciplinary setups, efficacy, and cost-effectiveness have to be proven

is article includes a short description of robotic structures and work

Dr. Thomas Sweeney,, Orthopaedic Surgeon, FL

have been doing minimally-invasive surgery since 1999. Mazor Robotics Renaissance®'s revolutionary approach to spinal surgery has transformed my practice so I no longer need to do any open thoracic and lumbar surgery..





^{1.} Based on published data: Cannestra, e-poster NASS 2014; Kantelhardt, ESJ 2011; Ringel, ESJ 2012, Roser, 2013.



^{2.} Freehand represents the average fluoro radiation exposure during a freehand operation as a baseline for comparison to Renaissance only.

Evidence-Based Medicine

MIS-ReFRESH Prospective Study (Presented at IMAST 2018)



Significantly fewer complications in robotic arm

 Compared to fluoro-guided, robotic-guided surgeries were at 3.1 times LOWER risk for a complication

Significantly fewer revisions in robotic arm


 Compared to fluoro-guided, robotic-guided surgeries were at 14.7 times LOWER risk for a revision

79% less fluoro time/screw in robotic arm

Significantly fewer complications and revisions in robotic arm also in single level cases


Caveats:


- Interim report only 110 control patients
- Only 2 surgeons in control arm
- Average Follow up 1.3 +0.8 years in robotic and control arm
- High event rate in fluoro-guided arm



MIS ReFRESH Prospective Study of Mazor Core Technology Patient Self-Evaluations









Business Model Three Revenue Pillars











Capital Sales

Mazor X & Upgrades

Distributor Sales

Renaissance

Direct Sales

Per Case Revenue

Disposable Kits

Synergy fee revenue:*
(*) under certain conditions

Per System Revenue

Annual Service revenues






H1 2018 Financial and Operating Highlights




- Robotic guidance systems sold in the first half of 2018 increased 32% over the first half of 2017
 - > Q1 increased by 42%
 - > Q2 increased by 25%
- Significant majority of systems sold and installed were to US customers
- H1/2018 financial performance and binding commitments for the Mazor X Stealth Edition position Mazor for revenue growth in H2 2018 compared to the H1 2018



Revenue Breakdown

Year Ended December, 2017







Income Statement



Income Statement					
	Year Ended December 31,		6 Months Ended June 30,		
(\$ in thousands)	2017	2016	2018	2017	
Revenue	\$64,947	\$36,379	\$28,745	\$27,174	
Cost of sales	\$23,684	\$10,330	\$12,272	\$8,875	
Gross Profit	\$41,263	\$26,049	\$16,473	\$18,299	
% margin	64%	72%	57%	67%	
Operating Expenses					
Research and development, net	\$8,192	\$5,736	\$5,069	\$4,034	
Selling and marketing, net	\$39,499	\$33,637	\$12,288	\$20,209	
General and administrative	\$7,375	\$5,697	\$4,442	\$3,657	
Total operating expenses	\$55,066	\$45,070	\$21,799	\$27,900	
% of revenue	85%	124%	76%	103%	
Loss from operations	(\$13,803)	(\$19,021)	(\$5,326)	(\$9,601)	
Net loss	(\$12,419)	(\$18,668)	(\$5,118)	(\$8,908)	



Balance Sheet



Consolidated Statements of Financial Position

	As of June 30,	As of December 31,	
(\$ in thousands)	2018	2017	
Assets	(Unaudited)	(Audited)	
Cash and Cash equivalent	\$37,475	\$46,376	
Short-term investments	\$66,796	\$56,708	
Trade receivables	\$9,401	\$5,460	
Other accounts receivable	\$2,936	\$2,054	
Inventory	\$7,130	\$7,864	
Total current assets	\$123,738	\$118,462	
Total non-current assets	\$11,233	\$12,534	
Total Assets	\$134,971	\$130,996	
Current liabilities	\$16,858	\$16,819	
Total non-current liabilities	\$454	\$414	
Equity	\$117,659	\$113,763	
Total liabilities and Equity	\$134,971	\$130,996	




Mazor Robotics 2018









Strategic Partnership with Medtronic for Mazor X

Ambulatory Surgery Center Strategy for the Renaissance

Leverage Robotics
Spine and Out-of-Spine